- Home
- BKYI vs SCNI Comparison
BKYI vs SCNI Comparison
Compare BKYI & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- SCNI
- Stock Information
- Founded
- BKYI 1993
- SCNI 2003
- Country
- BKYI United States
- SCNI Israel
- Employees
- BKYI N/A
- SCNI N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BKYI Technology
- SCNI Health Care
- Exchange
- BKYI Nasdaq
- SCNI Nasdaq
- Market Cap
- BKYI 3.2M
- SCNI 3.5M
- IPO Year
- BKYI 1997
- SCNI N/A
- Fundamental
- Price
- BKYI $0.94
- SCNI $2.84
- Analyst Decision
- BKYI
- SCNI
- Analyst Count
- BKYI 0
- SCNI 0
- Target Price
- BKYI N/A
- SCNI N/A
- AVG Volume (30 Days)
- BKYI 6.3M
- SCNI 12.9K
- Earning Date
- BKYI 11-14-2024
- SCNI 11-29-2024
- Dividend Yield
- BKYI N/A
- SCNI N/A
- EPS Growth
- BKYI N/A
- SCNI N/A
- EPS
- BKYI N/A
- SCNI N/A
- Revenue
- BKYI $7,292,394.00
- SCNI $284,000.00
- Revenue This Year
- BKYI N/A
- SCNI N/A
- Revenue Next Year
- BKYI $24.64
- SCNI N/A
- P/E Ratio
- BKYI N/A
- SCNI N/A
- Revenue Growth
- BKYI N/A
- SCNI N/A
- 52 Week Low
- BKYI $0.52
- SCNI $2.23
- 52 Week High
- BKYI $4.50
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- BKYI 45.22
- SCNI 30.31
- Support Level
- BKYI $1.13
- SCNI $2.91
- Resistance Level
- BKYI $1.31
- SCNI $3.70
- Average True Range (ATR)
- BKYI 0.17
- SCNI 0.21
- MACD
- BKYI -0.01
- SCNI -0.07
- Stochastic Oscillator
- BKYI 1.93
- SCNI 7.37
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.